EYEG - EyeGate Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3550
+0.0060 (+1.72%)
As of 12:25PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.3490
Open0.3600
Bid0.3532 x 800
Ask0.3600 x 900
Day's Range0.3503 - 0.3600
52 Week Range0.2900 - 1.3800
Volume83,588
Avg. Volume455,907
Market Cap15.421M
Beta2.59
PE Ratio (TTM)N/A
EPS (TTM)-0.5430
Earnings DateMay 7, 2018 - May 11, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire16 days ago

    EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies

    EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first three patients have been randomized in its study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to reduce corneal staining – a sign of ocular surface damage - in patients with punctate epitheliopathies (PE) due to pathologies such as dry eye. Randomization occurs if a patient meets specific clinical criteria after a two-week qualification period and can then enter the treatment phase of the study. EyeGate’s other ongoing OBG study which is for patients that have large corneal defects due to photorefractive keratectomy (PRK) surgery is currently greater than 80% enrolled.

  • GlobeNewswire16 days ago

    EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis

    EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced top-line results from its Phase 3 study evaluating the safety and efficacy of EGP-437 delivered through the EyeGate® II Drug Delivery System (EGDS) in patients with non-infectious anterior segment uveitis. Although EGP-437 showed clinical efficacy, defined as a reduction in anterior chamber cell score throughout the study, it did not demonstrate non-inferiority to the prednisolone acetate ophthalmic solution control group. This also represents an opportunity to shift our focus toward the key clinical trials that support our innovative Ocular Bandage Gel (OBG) product, which has the potential to benefit patients with corneal surface damage.  We are actively enrolling for the PRK (photorefractive keratectomy) and PE (punctate epitheliopathy) studies, both of which are on track for announcement of top-line data in the fourth quarter of 2018.

  • GlobeNewswire22 days ago

    EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference

    EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the Company will present at the upcoming H.C. Wainwright 20th Annual Global Investment Conference,  being held on September 4-6, 2018 at the St. Regis Hotel in New York City. The presentation will be available on EyeGate Pharmaceutical's website. EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products using its two proprietary platform technologies for treating diseases and disorders of the eye.

  • GlobeNewswirelast month

    EyeGate Announces Enrollment of First Patient in PRK Pilot Study

    EyeGate Pharmaceuticals, Inc. (EYEG) a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced that the first patient has been enrolled in its pilot study evaluating the ability of EyeGate’s Ocular Bandage Gel (OBG) to accelerate re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK) surgery. The PRK pilot study will enroll up to 45 subjects undergoing a bilateral procedure in a reading center masked trial.

  • GlobeNewswirelast month

    EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s annual stockholders meeting on July 10, 2018. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Peter Greenleaf to the EyeGate Board.

  • GlobeNewswire2 months ago

    EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three month period ended June 30, 2018, and provided an update on recent corporate and operational activities. Stephen From, EyeGate’s Chief Executive Officer, said, “We continue to hit operational milestones, which culminated with the FDA’s approval of our two IDE submissions, allowing us to move forward with clinical trials for the EyeGate Ocular Bandage Gel in two indications.” Mr. From continued, “Additionally, we added two new Board members, who each bring a wealth of biopharmaceutical experience to EyeGate.

  • Zacks Small Cap Research2 months ago

    EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off

    As we noted in our Q1 ’18 earnings update in late-May, Eyegate Pharmaceuticals' (EYEG) diligence in rapidly responding to FDAs follow-on questions related to their IDE submission has been key to keeping their Ocular Bandage Gel (OBG) programs on-track with updated forecasted timelines. EYEG had previously been guiding for commencement of both studies during Q3 (i.e.

  • EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24
    Market Realist2 months ago

    EyeGate Pharmaceuticals Stock Rose ~5.8% on July 24

    On July 24, EyeGate Pharmaceuticals (EYEG) announced that it has secured FDA approval for two investigational device exemption applications related to pilot studies for the company’s OBG (ocular bandage gel) product scheduled to commence in the third quarter. In one pivotal study, the company will compare the OBG (or CHMA-S) product with the combination of bandage contact lens and artificial tears, which is the current standard of care for patients who have undergone photorefractive keratectom and require accelerated re-epithelialization of the corneal wounds.

  • GlobeNewswire2 months ago

    EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel

    EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the U.S. Food and Drug Administration (FDA) has approved two of EyeGate’s Investigational Device Exemption (IDE) applications for pilot studies of the company’s Ocular Bandage Gel (OBG) product for the acceleration of re-epithelialization of large corneal epithelial defects in patients having undergone photorefractive keratectomy (PRK), as well as the reduction in corneal staining for patients with punctate epitheliopathies (PE). EyeGate anticipates entering the clinic for both indications in the third quarter of 2018.

  • ACCESSWIRE2 months ago

    Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want a free Stock Review on FGEN sign up now at www.wallstequities.com/registration. Pre-market, WallStEquities.com evaluates EyeGate Pharmaceuticals Inc. (NASDAQ: EYEG), EyePoint Pharmaceuticals Inc. (NASDAQ: EYPT), Fate Therapeutics Inc. (NASDAQ: FATE), and FibroGen Inc. (NASDAQ: FGEN).

  • ACCESSWIRE3 months ago

    Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia

    LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want access to our free research report on FibroGen, Inc. (NASDAQ: FGEN), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=FGEN as the Company's latest news hit the wire. On June 07, 2018, the Company announced that it has completed patient enrollment in the Phase-3 studies supporting the US new drug application (NDA) submission for Roxadustat in anemia associated with chronic kidney disease (CKD).

  • Zacks Small Cap Research4 months ago

    EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start

    Through Q1 2018, EYEG collected $12.5M related to upfront payments and development milestones from the two Valeant agreements related to EGP-437 programs in anterior uveitis and post-cataract surgery. While FDA’s requests have resulted in delays in getting the IDE through the approval process, EYEG has been diligent in responding to their questions – which has been key to keeping timelines intact.

  • Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed Lately
    Simply Wall St.4 months ago

    Want To Invest In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)? Here’s How It Performed Lately

    Examining how EyeGate Pharmaceuticals Inc (NASDAQ:EYEG) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...

  • Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?
    Simply Wall St.4 months ago

    Are Insiders Too Confident In EyeGate Pharmaceuticals Inc (NASDAQ:EYEG)?

    EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing products for treating diseases and disorders of the eye. EyeGate Pharmaceuticals is one of United States’s small-capRead More...